Received Jun 10, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | TL74Y | — |
Administration after Below temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a adult female patient who received Herpes zoster (Shingrix) solution for injection (batch number TL74Y) for prophylaxis. On 20-MAY-2026, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced incorrect storage of drug (Verbatim: Administration after Below temperature excursion). The outcome of the incorrect storage of drug was not applicable. Additional Information: GSK Receipt Date: 04-JUN-2026 On 04-June-2026, a Medical Assistant reported via chat an excursion (that happened on 11-May-2026) for Boostrix, Engerix-B, Havrix, Menveo (1 vial), and Shingrix (PFS) vaccines, with a minimum temperature of 30-degree F for 2 hours. The AMAS asked if the patient needed to be revaccinated.; Sender's Comments: US-GSK-US2026074479:SAME REPORTER US-GSK-US2026074478:SAME REPORTER US-GSK-US2026074480:SAME REPORTER US-GSK-US2026074484:SAME REPORTER US-GSK-US2026074706:SAME REPORTER